Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 04, 2022 04:38 ET | Source: Research and Markets

LAMEA Idiopathic Pulmonary Fibrosis Market Report 2022: Featuring Key Players GNI Group, AstraZeneca, Bristol Myers Squibb & Others

Dublin, Aug. 04, 2022 (GLOBE NEWSWIRE) -- The "LAMEA Idiopathic Pulmonary Fibrosis Market Size, Share & Industry Trends Analysis Report By Drug Type, By Distribution Channel (Retail Pharmacies,...
May 19, 2022 05:03 ET | Source: Research and Markets

APAC Idiopathic Pulmonary Fibrosis Market to 2027 - Size, Share & Industry Trends Analysis Report

Dublin, May 19, 2022 (GLOBE NEWSWIRE) -- The "Asia Pacific Idiopathic Pulmonary Fibrosis Market Size, Share & Industry Trends Analysis Report By Drug Type, By Distribution Channel (Retail...
April 25, 2022 07:08 ET | Source: Research and Markets

The Worldwide Idiopathic Pulmonary Fibrosis Industry is Expected to Reach $4.7 Billion by 2027

Dublin, April 25, 2022 (GLOBE NEWSWIRE) -- The "Global Idiopathic Pulmonary Fibrosis Market Size, Share & Industry Trends Analysis Report By Drug Type, By Distribution Channel (Retail...
March 31, 2022 06:13 ET | Source: Research and Markets

The Worldwide Idiopathic Pulmonary Fibrosis Industry is Projected to Reach $6 Billion by 2030

Dublin, March 31, 2022 (GLOBE NEWSWIRE) -- The "Idiopathic Pulmonary Fibrosis Market by Drug Type and Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2021-2030" report has...
February 28, 2022 06:23 ET | Source: Research and Markets

Global Idiopathic Pulmonary Fibrosis (IPF) Industry Forecast, 2030 - Competitive Landscape Assessment, Product Development & Innovation, Case Reports, Marketed Products & Emerging Therapies

Dublin, Feb. 28, 2022 (GLOBE NEWSWIRE) -- The "Global Idiopathic Pulmonary Fibrosis Market, By Therapy, Estimation & Forecast, 2017-2030" report has been added to ResearchAndMarkets.com's...
January 20, 2022 04:43 ET | Source: Research and Markets

Global Idiopathic Pulmonary Fibrosis (IPF) Market Report 2021: Market was Valued at $3271.3 Million in 2020 - Forecast to 2026

Dublin, Jan. 20, 2022 (GLOBE NEWSWIRE) -- The "Global Idiopathic Pulmonary Fibrosis (IPF) Market - Analysis By Drug Type, End User, By Region, By Country (2021 Edition): Market Insights, Pipeline...
December 30, 2020 08:58 ET | Source: Research and Markets

Esbriet (Pirfenidone): An Oral Anti-fibrotic Medicine Approved for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) - Global Drug Insight and Market Forecasts, 2017-2030

Dublin, Dec. 30, 2020 (GLOBE NEWSWIRE) -- The "Esbriet (Pirfenidone) - Drug Insight and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering. Esbriet (pirfenidone) -...
December 10, 2020 04:33 ET | Source: Research and Markets

Global Idiopathic Pulmonary Fibrosis Treatment Market Report 2020: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2014-2025

Dublin, Dec. 10, 2020 (GLOBE NEWSWIRE) -- The "Idiopathic Pulmonary Fibrosis Treatment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025" report has been added...
December 30, 2014 14:05 ET | Source: Coalition for Pulmonary Fibrosis (CPF)

CPF Celebrates Historic Year of Progress in Pulmonary Fibrosis

CULVER CITY, Calif., Dec. 30, 2014 (GLOBE NEWSWIRE) -- The Coalition for Pulmonary Fibrosis (CPF) played an important role in much of the year's successes in Pulmonary Fibrosis (PF), helping to make...
October 16, 2014 17:19 ET | Source: Coalition for Pulmonary Fibrosis (CPF)

CORRECTION - Two FDA Approvals on Same Day Renew Hope for Pulmonary Fibrosis Community

CULVER CITY, CALIF., Oct. 16, 2014 (GLOBE NEWSWIRE) -- In its press release dated October 16, 2014 at 10:46 AM EST with the headline "Two FDA Approvals on Same Day Renew Hope for Pulmonary Fibrosis...